ArticleFrontiers in pharmacology2026
Off-label prescribing in ophthalmology: a retrospective analysis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Off-label practice is often needed in ophthalmology, due to the limited number of drugs approved to treat several ocular diseases and to manage challenging ocular surgeries. The aim was to analyze the off-label drug prescriptions issued from January 2014 to December 2024 at the Department of Ophthalmology of the University Hospital of Catania (Italy). 233 off-label prescriptions, comprising 13 drugs, were delivered to treat 225 patients affected by ocular disorders. Results of the present study showed a raise of off-label prescriptions in 2015 and 2016 mainly due to mitomycin C use in trabeculectomy, representing 34.3% of the total off-label drug prescriptions in the reference period. After a decrease in 2017-2018, there was an increasing trend in the number of off-label issued prescriptions until 2024. The main contributors were anti-vascular endothelial growth factor (VEGF) drugs such as bevacizumab, ranibizumab and aflibercept, which represent 25.3%, 9.0% and 4.3% of off-label prescriptions, respectively. Additionally, 5-fluorouracil and dexamethasone were prescribed off-label, each representing 7.3% of the total off-label prescriptions, to mainly handle conjunctival carcinoma and various macular edema, respectively. Alteplase (6.9%), voriconazole (2.1%), verteporfin (1.3%), and foscarnet (0.9%), together with amphotericin B (0.4%), ganciclovir (0.4%), as well as rituximab (0.4%) were off-label prescribed to manage other specific ocular conditions. These results suggest that off-label practice is evolving in the field of ophthalmology. Collaboration among regulatory authorities, clinicians, marketing authorization holders, and patients is essential, in order to develop standardized, evidence-based international guidelines about off-label use, to improve outcome of patients with unmet medical needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.